Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNPXNASDAQ:HOOKNASDAQ:HUGENASDAQ:MGTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNPXGENPREX$0.23-9.6%$0.28$0.20▼$3.97$6.96M-0.414.12 million shs2.84 million shsHOOKHOOKIPA Pharma$1.26-3.1%$1.33$0.72▼$6.77$15.85M0.9682,744 shs30,210 shsHUGEFSD Pharma$0.23$0.11$0.07▼$1.68$9.11M0.610.14 million shsN/AMGTAMagenta Therapeutics$0.70-7.7%$0.53$0.32▼$2.07$42.44M2.12848,835 shs376,000 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNPXGENPREX+9.17%-16.67%-9.09%-34.21%-87.62%HOOKHOOKIPA Pharma+2.36%-0.76%-13.91%+6.56%-79.63%HUGEFSD Pharma0.00%0.00%0.00%+152.50%+25.76%MGTAMagenta Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNPXGENPREX0.5887 of 5 stars0.02.00.04.70.00.00.6HOOKHOOKIPA Pharma2.4675 of 5 stars3.25.00.00.00.61.70.6HUGEFSD PharmaN/AN/AN/AN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNPXGENPREX 0.00N/AN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50257.14% UpsideHUGEFSD Pharma 0.00N/AN/AN/AMGTAMagenta Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNPXGENPREXN/AN/AN/AN/A$0.15 per shareN/AHOOKHOOKIPA Pharma$43.95M0.35N/AN/A$4.25 per share0.30HUGEFSD PharmaN/AN/AN/AN/A$0.33 per shareN/AMGTAMagenta TherapeuticsN/AN/AN/AN/A$1.23 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNPXGENPREX-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)HUGEFSD Pharma-$17.90M-$0.26N/AN/AN/AN/A-74.06%-55.31%N/AMGTAMagenta Therapeutics-$76.46MN/A0.00∞N/AN/A-70.88%-57.27%N/ALatest MGTA, GNPX, HUGE, and HOOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/12/2025Q1 2025GNPXGENPREX-$0.82-$0.26+$0.56-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNPXGENPREXN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AHUGEFSD PharmaN/AN/AN/AN/AN/AMGTAMagenta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNPXGENPREXN/A1.941.94HOOKHOOKIPA PharmaN/A3.613.61HUGEFSD PharmaN/A2.342.34MGTAMagenta TherapeuticsN/A19.4919.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNPXGENPREX14.05%HOOKHOOKIPA Pharma63.88%HUGEFSD Pharma1.24%MGTAMagenta Therapeutics47.53%Insider OwnershipCompanyInsider OwnershipGNPXGENPREX8.47%HOOKHOOKIPA Pharma3.30%HUGEFSD Pharma8.53%MGTAMagenta Therapeutics15.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNPXGENPREX2027.82 million25.47 millionNo DataHOOKHOOKIPA Pharma5612.19 million11.79 millionOptionableHUGEFSD Pharma1740.12 million36.70 millionOptionableMGTAMagenta Therapeutics6760.67 million51.46 millionNot OptionableMGTA, GNPX, HUGE, and HOOK HeadlinesRecent News About These CompaniesMagenta Skateboards 15-Year Anniversary Show in Paris, June 20-23June 12, 2025 | msn.comThird Time's the Charm: Magenta Giving Month Breaks Records With $3.3M in Donations, 27K+ Volunteer HoursMay 19, 2025 | finance.yahoo.comMontra Electric signs pact with Magenta Mobility for supply of 100 eSCVsApril 23, 2025 | dailyexcelsior.comDMagenta Token Pre-Sale Now Live: Pioneering a New Era in the MagentaVerse EcosystemNovember 15, 2024 | markets.businessinsider.comMagenta Project: Sam Davies, Pip Hare, and Mariana Lobato share their pathwaysNovember 7, 2024 | sail-world.comSMagenta Mobility’s FY24 revenue rises three fold, losses widen by 17.1%November 7, 2024 | yourstory.comYFanfulla - Magenta head to head game preview and predictionNovember 5, 2024 | afootballreport.comAMagenta Hotels makes first Northern acquisitionOctober 28, 2024 | placenorthwest.co.ukPVIRAL | Chattisgarh Man's Desi Recreation Of Magenta Riddim Impresses DJ Snake, Netizens ReactOctober 20, 2024 | republicworld.comRCasatese - Magenta head to head game preview and predictionOctober 19, 2024 | afootballreport.comAOculi Launches Early Access Evaluation Program with Magenta and Burgundy PlatformsOctober 15, 2024 | 01net.it0Magenta Living and Seddon team up to help apprentices using Widnes-based developmentOctober 11, 2024 | msn.comMagenta Living and Bolton-based Seddon Housing Partnerships team up to help apprenticesOctober 9, 2024 | msn.comMagenta Mobility expands its fleet to over 2,000 EVsOctober 4, 2024 | electrive.comEMagenta Associates becomes employee ownedOctober 1, 2024 | workplaceinsight.netWMagenta Mobility Achieves Major Milestone With Over 2,000 Electric Vehicles In IndiaSeptember 28, 2024 | drivespark.comDMagenta sharing gas safety advice at pop-ups this weekSeptember 11, 2024 | msn.comChhattisgarh DJ’s desi twist to ‘Magenta Riddim’ impresses DJ Snake, viral video stuns the internetSeptember 2, 2024 | indianexpress.comIDelhi Metro Phase-IV: Safety nod in, Magenta Line extension may open next monthAugust 30, 2024 | msn.comLive in Studio B, Wednesday at 11am: Magenta SunshineAugust 26, 2024 | wncw.orgWNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookAXON: Competition Intensifies as Motorola Makes $4.4B AcquisitionBy Leo Miller | May 31, 2025View AXON: Competition Intensifies as Motorola Makes $4.4B AcquisitionAmer Sports: The New ONON and DECK of Consumer Discretionary?By Leo Miller | May 28, 2025View Amer Sports: The New ONON and DECK of Consumer Discretionary?3 Auto Chip Stocks Up 60%+ From 2025 Lows: More Gains Ahead?By Leo Miller | June 18, 2025View 3 Auto Chip Stocks Up 60%+ From 2025 Lows: More Gains Ahead?Regional Bank Buybacks: 5 Institutions Making Big MovesBy Leo Miller | June 24, 2025View Regional Bank Buybacks: 5 Institutions Making Big MovesMGTA, GNPX, HUGE, and HOOK Company DescriptionsGENPREX NASDAQ:GNPX$0.23 -0.02 (-9.56%) Closing price 04:00 PM EasternExtended Trading$0.23 +0.00 (+1.28%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.HOOKIPA Pharma NASDAQ:HOOK$1.26 -0.04 (-3.08%) Closing price 04:00 PM EasternExtended Trading$1.26 0.00 (0.00%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.FSD Pharma NASDAQ:HUGEFSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.Magenta Therapeutics NASDAQ:MGTAMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
